CA2905594A1 - Compositions for use in treating eye disorders using dipyridamole - Google Patents
Compositions for use in treating eye disorders using dipyridamole Download PDFInfo
- Publication number
- CA2905594A1 CA2905594A1 CA2905594A CA2905594A CA2905594A1 CA 2905594 A1 CA2905594 A1 CA 2905594A1 CA 2905594 A CA2905594 A CA 2905594A CA 2905594 A CA2905594 A CA 2905594A CA 2905594 A1 CA2905594 A1 CA 2905594A1
- Authority
- CA
- Canada
- Prior art keywords
- dipyridamole
- eye
- composition
- topically
- effective amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 title claims abstract description 60
- 229960002768 dipyridamole Drugs 0.000 title claims abstract description 60
- 239000000203 mixture Substances 0.000 title claims abstract description 47
- 208000030533 eye disease Diseases 0.000 title claims abstract description 15
- 150000003839 salts Chemical class 0.000 claims abstract description 4
- 210000000795 conjunctiva Anatomy 0.000 claims description 5
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 31
- 239000006196 drop Substances 0.000 description 29
- 210000001508 eye Anatomy 0.000 description 29
- 206010013774 Dry eye Diseases 0.000 description 28
- 238000009472 formulation Methods 0.000 description 21
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 18
- 208000024891 symptom Diseases 0.000 description 16
- 239000011780 sodium chloride Substances 0.000 description 14
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 208000031973 Conjunctivitis infective Diseases 0.000 description 11
- 201000001028 acute contagious conjunctivitis Diseases 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 208000009329 Graft vs Host Disease Diseases 0.000 description 9
- 208000002193 Pain Diseases 0.000 description 9
- 206010012601 diabetes mellitus Diseases 0.000 description 9
- 208000024908 graft versus host disease Diseases 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 206010002091 Anaesthesia Diseases 0.000 description 8
- 201000002154 Pterygium Diseases 0.000 description 8
- 230000037005 anaesthesia Effects 0.000 description 8
- 201000007717 corneal ulcer Diseases 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 206010064996 Ulcerative keratitis Diseases 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 210000004087 cornea Anatomy 0.000 description 6
- 239000003889 eye drop Substances 0.000 description 6
- 229940012356 eye drops Drugs 0.000 description 6
- 230000036407 pain Effects 0.000 description 6
- 208000025865 Ulcer Diseases 0.000 description 5
- 239000008223 sterile water Substances 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 4
- 206010046851 Uveitis Diseases 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000036512 infertility Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 206010023332 keratitis Diseases 0.000 description 4
- 206010069732 neurotrophic keratopathy Diseases 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 230000036470 plasma concentration Effects 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- 231100000397 ulcer Toxicity 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 206010022941 Iridocyclitis Diseases 0.000 description 3
- 201000002287 Keratoconus Diseases 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 201000004612 anterior uveitis Diseases 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 210000003683 corneal stroma Anatomy 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- 210000003786 sclera Anatomy 0.000 description 3
- 230000035807 sensation Effects 0.000 description 3
- 210000002536 stromal cell Anatomy 0.000 description 3
- 230000001052 transient effect Effects 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 206010010741 Conjunctivitis Diseases 0.000 description 2
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 2
- 206010010984 Corneal abrasion Diseases 0.000 description 2
- 208000028006 Corneal injury Diseases 0.000 description 2
- 206010055665 Corneal neovascularisation Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010029113 Neovascularisation Diseases 0.000 description 2
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 2
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 2
- 208000000222 Viral Eye Infections Diseases 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 206010047513 Vision blurred Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 208000002205 allergic conjunctivitis Diseases 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 208000024998 atopic conjunctivitis Diseases 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000036765 blood level Effects 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 230000003366 colagenolytic effect Effects 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 208000021921 corneal disease Diseases 0.000 description 2
- 201000000159 corneal neovascularization Diseases 0.000 description 2
- 238000009109 curative therapy Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 239000003885 eye ointment Substances 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 206010023365 keratopathy Diseases 0.000 description 2
- 201000004768 pinguecula Diseases 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 210000001745 uvea Anatomy 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 208000016134 Conjunctival disease Diseases 0.000 description 1
- 101000783577 Dendroaspis angusticeps Thrombostatin Proteins 0.000 description 1
- 101000783578 Dendroaspis jamesoni kaimosae Dendroaspin Proteins 0.000 description 1
- 201000001925 Fuchs' endothelial dystrophy Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 208000014260 Fungal keratitis Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 206010062353 Keratitis fungal Diseases 0.000 description 1
- 208000009319 Keratoconjunctivitis Sicca Diseases 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 206010052143 Ocular discomfort Diseases 0.000 description 1
- 208000023715 Ocular surface disease Diseases 0.000 description 1
- 102000012404 Orosomucoid Human genes 0.000 description 1
- 108010061952 Orosomucoid Proteins 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 description 1
- 206010034944 Photokeratitis Diseases 0.000 description 1
- 206010062889 Pingueculitis Diseases 0.000 description 1
- 241001621636 Pterygia Species 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 241000593989 Scardinius erythrophthalmus Species 0.000 description 1
- 206010039705 Scleritis Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000010011 Vitamin A Deficiency Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000003732 agents acting on the eye Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 201000009310 astigmatism Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 230000010036 cardiovascular benefit Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000003161 choroid Anatomy 0.000 description 1
- 210000004240 ciliary body Anatomy 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007887 coronary angioplasty Methods 0.000 description 1
- 239000003218 coronary vasodilator agent Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003560 epithelium corneal Anatomy 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 201000004356 excessive tearing Diseases 0.000 description 1
- 230000028023 exocytosis Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000030214 innervation Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000000554 iris Anatomy 0.000 description 1
- 201000004614 iritis Diseases 0.000 description 1
- 230000005722 itchiness Effects 0.000 description 1
- 210000004561 lacrimal apparatus Anatomy 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 201000005111 ocular hyperemia Diseases 0.000 description 1
- 229940023490 ophthalmic product Drugs 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000036281 parasite infection Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- JOZPEVMCAKXSEY-UHFFFAOYSA-N pyrimido[5,4-d]pyrimidine Chemical class N1=CN=CC2=NC=NC=C21 JOZPEVMCAKXSEY-UHFFFAOYSA-N 0.000 description 1
- 238000011555 rabbit model Methods 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000009861 stroke prevention Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000004488 tear evaporation Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 210000003901 trigeminal nerve Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL225179 | 2013-03-12 | ||
| IL225179A IL225179A (en) | 2013-03-12 | 2013-03-12 | Compounds for use in ocular disorders using dipyridamole |
| PCT/IB2014/059645 WO2014141079A1 (en) | 2013-03-12 | 2014-03-11 | Compositions for use in treating eye disorders using dipyridamole |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2905594A1 true CA2905594A1 (en) | 2014-09-18 |
Family
ID=48916407
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2905594A Abandoned CA2905594A1 (en) | 2013-03-12 | 2014-03-11 | Compositions for use in treating eye disorders using dipyridamole |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP2968328A4 (ko) |
| JP (1) | JP6820658B2 (ko) |
| KR (2) | KR20150126021A (ko) |
| CN (1) | CN105188702B (ko) |
| AU (1) | AU2014229371B2 (ko) |
| BR (1) | BR112015022084A2 (ko) |
| CA (1) | CA2905594A1 (ko) |
| CL (1) | CL2015002627A1 (ko) |
| EA (1) | EA035966B1 (ko) |
| IL (1) | IL225179A (ko) |
| MX (1) | MX2015012716A (ko) |
| MY (1) | MY182591A (ko) |
| SG (2) | SG10201706937UA (ko) |
| WO (1) | WO2014141079A1 (ko) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6925272B2 (ja) * | 2015-01-28 | 2021-08-25 | リアルイン ライフ サイエンス リミテッド | ＰＰＡＲγ発現および核転座を促進する化合物およびそれの治療的使用 |
| US20180092776A1 (en) | 2016-09-30 | 2018-04-05 | Sara Heikali | Method and device for treating and managing diseased ocular tissue |
| WO2021001806A1 (en) | 2019-07-04 | 2021-01-07 | Ocular Discovery Ltd. | Stable dipyridamole formulations with reduced impurities |
| WO2021001805A1 (en) | 2019-07-04 | 2021-01-07 | Ocular Discovery Ltd. | Stable dipyridamole formulations and their methods of preparation |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07258084A (ja) * | 1994-03-17 | 1995-10-09 | Rohto Pharmaceut Co Ltd | ジピリダモールを必須成分とする眼圧降下剤 |
| US5780450A (en) * | 1995-11-21 | 1998-07-14 | Alcon Laboratories, Inc. | Use of adenosine uptake inhibitors for treating retinal or optic nerve head damage |
| US20060104968A1 (en) * | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| NZ568694A (en) * | 2005-11-09 | 2011-09-30 | Zalicus Inc | Method, compositions, and kits for the treatment of medical conditions |
| WO2010056710A1 (en) * | 2008-11-11 | 2010-05-20 | Biovista, Inc. | Compositions and methods for treating eye diseases |
| EP2363126A1 (en) * | 2010-03-04 | 2011-09-07 | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. | Composition comprising as active ingredient L-carnitine in combination with hydroxykynurenine-O-beta-DL-glucoside, for the prevention and/or treatment of pathologies of the eye due to ultraviolet radiation |
-
2013
- 2013-03-12 IL IL225179A patent/IL225179A/en active IP Right Grant
-
2014
- 2014-03-11 EA EA201591653A patent/EA035966B1/ru unknown
- 2014-03-11 BR BR112015022084A patent/BR112015022084A2/pt active Search and Examination
- 2014-03-11 EP EP14764673.1A patent/EP2968328A4/en not_active Withdrawn
- 2014-03-11 CN CN201480016302.6A patent/CN105188702B/zh not_active Expired - Fee Related
- 2014-03-11 KR KR1020157027571A patent/KR20150126021A/ko not_active IP Right Cessation
- 2014-03-11 SG SG10201706937UA patent/SG10201706937UA/en unknown
- 2014-03-11 AU AU2014229371A patent/AU2014229371B2/en not_active Ceased
- 2014-03-11 MX MX2015012716A patent/MX2015012716A/es unknown
- 2014-03-11 SG SG11201507092QA patent/SG11201507092QA/en unknown
- 2014-03-11 MY MYPI2015002196A patent/MY182591A/en unknown
- 2014-03-11 WO PCT/IB2014/059645 patent/WO2014141079A1/en active Application Filing
- 2014-03-11 JP JP2015562486A patent/JP6820658B2/ja active Active
- 2014-03-11 KR KR1020217001495A patent/KR20210010638A/ko not_active Application Discontinuation
- 2014-03-11 CA CA2905594A patent/CA2905594A1/en not_active Abandoned
-
2015
- 2015-09-11 CL CL2015002627A patent/CL2015002627A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2968328A4 (en) | 2016-11-23 |
| AU2014229371B2 (en) | 2018-05-10 |
| SG11201507092QA (en) | 2015-10-29 |
| SG10201706937UA (en) | 2017-09-28 |
| JP2016514123A (ja) | 2016-05-19 |
| CL2015002627A1 (es) | 2016-03-11 |
| EA035966B1 (ru) | 2020-09-07 |
| EP2968328A1 (en) | 2016-01-20 |
| EA201591653A1 (ru) | 2017-05-31 |
| CN105188702B (zh) | 2019-03-26 |
| MX2015012716A (es) | 2016-07-06 |
| MY182591A (en) | 2021-01-26 |
| KR20150126021A (ko) | 2015-11-10 |
| KR20210010638A (ko) | 2021-01-27 |
| IL225179A0 (en) | 2013-06-27 |
| WO2014141079A1 (en) | 2014-09-18 |
| JP6820658B2 (ja) | 2021-01-27 |
| CN105188702A (zh) | 2015-12-23 |
| IL225179A (en) | 2017-01-31 |
| BR112015022084A2 (pt) | 2017-07-18 |
| AU2014229371A1 (en) | 2015-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5583310B2 (ja) | 眼球の症状の予防及び治療のための眼科用製剤 | |
| EP1904108B1 (en) | Ophthalmological formulation comprising methylsulfonylmethane and ciprofloxacin | |
| KR20100067684A (ko) | 약물 전달을 위한 비히클로서의 수불혼화성 물질 | |
| JP2009501726A (ja) | 眼科学的活性剤の製剤とその投与の方法 | |
| US10973758B2 (en) | Methods of eye treatment using therapeutic compositions containing dipyridamole | |
| CA2801145A1 (en) | N-acetyl-dl-leucine, neuroprotective and retinoprotective medicament | |
| RU2602738C2 (ru) | Комбинация фолиевой кислоты и рамиприла: цитопротекторные, нейропротекторные и ретинопротекторные офтальмологические композиции | |
| AU2014229371B2 (en) | Compositions for use in treating eye disorders using dipyridamole | |
| US9254289B2 (en) | Methods for treating eye disorders using dipyridamole | |
| RU2485939C1 (ru) | Офтальмологический препарат в виде глазных капель, содержащий дисульфирам и таурин | |
| US10322129B2 (en) | Therapeutic compositions containing dipyridamole, treatment packs and kits including such compositions and methods for producing same | |
| CN116981457A (zh) | 有效预防、控制和根除老花眼的低浓度剂量的协同眼科组合物 | |
| JP7197112B2 (ja) | 水泡性角膜症治療用医薬組成物 | |
| US8853257B2 (en) | Succinimide derivatives as ocular hypotensive agents | |
| TW202002980A (zh) | 選擇性syk抑制劑之使用方法及醫藥組合物 | |
| US20140213605A1 (en) | Methods for treating eye disorders using opioid receptor antagonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20190115 |
|
| FZDE | Discontinued |
Effective date: 20230104 |
|
| FZDE | Discontinued |
Effective date: 20230104 |